Influenza Clinical Trial
Official title:
Multicenter, Double-blind, Comparative, Randomized Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years
Verified date | March 2022 |
Source | St. Petersburg Research Institute of Vaccines and Sera |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Comparative assessment of the tolerability, safety, and immunogenicity of the Flu-M® Inactivated Split Influenza Vaccine (without preservative) and the Flu-M® vaccine (with preservative) in volunteers aged between 18 and 60
Status | Completed |
Enrollment | 654 |
Est. completion date | November 15, 2021 |
Est. primary completion date | September 3, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: 1. Healthy volunteers (men and women) aged 18-60 years; 2. Written informed consent of volunteers to participate in the clinical trial; 3. Volunteers able to fulfill requirements of the Protocol (i.e. fill out the patient's diary, come to follow-up visits); 4. For fertile women - a negative result of the pregnancy test and consent to observe adequate methods of contraception during the trial and at least two months after vaccination 5. For fertile men - consent to observe adequate methods of contraception during the trial and at least two months after vaccination, except for men after vasectomy with documented azoospermia, and their sexual partners should use methods of contraception that ensure more than 90% reliability or be incapable of conception after a surgical sterilization or have a natural menopause for at least 2 years. Exclusion Criteria: 1. History of influenza/ARVI or previous influenza vaccination during 6 months before the trial; 2. Positive result of the SARS-CoV-2 test; 3. A serious post-vaccination reaction (temperature above 40 °C, hyperemia or edema more than 8 cm in diameter) or complications (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions accompanied or not accompanied by a fever due to any previous vaccination); 4. Allergic reactions to vaccine components or any previous vaccination; 5. History of allergic reaction to chicken protein; 6. Guillain-Barré syndrome (acute polyneuropathy) in the medical history; 7. Previous vaccination with rabies vaccines less than 2 months before immunization or scheduled vaccination with rabies vaccines within 1 month after immunization with the trial vaccines; 8. Use of any vaccines within 1 month before the vaccination, excluding vaccines according to the National Calendar of Preventive Vaccination, including for epidemic reasons; 9. History of leukemia, cancer, autoimmune diseases; 10. (Positive blood test results for HIV, syphilis, hepatitis B/C; 11. Volunteers who received immunoglobulin or blood products or had a blood transfusion during the last three months before the trial; 12. History of long-term use (more than 14 days) of immunosuppressants or immunomodulatory drugs for six months before the trial; 13. History of any confirmed or suspected immunosuppressive or immunodeficiency condition; 14. History of chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, the gastrointestinal tract, liver, kidneys, hematopoietic or immune systems, mental disease in the acute stage or in the decompensation stage (recovery less than 4 weeks before vaccination); 15. Diabetes mellitus, thyrotoxicosis or other diseases of the endocrine system; 16. History of eczema; 17. Treatment with glucocorticosteroids, including in small doses, as well as local use of drugs containing steroids (> 10 mg of prednisolone or its equivalent for more than 14 days before the screening); 18. Tuberculosis, neurological or mental disorders, a convulsive syndrome, including in the past medical history; 19. History of acute infectious diseases (recovery less than 4 weeks before vaccination); 20. Consumption of more than 10 units of alcohol per week or history of alcohol addiction, drug addiction or abuse of pharmaceutical products; 21. Smoking of more than 10 cigarettes per day; 22. Participation in another clinical trial during the last 3 months; 23. Pregnancy or lactation; 24. Coagulopathy, including hemophilia; 25. Taking aspirin or other antiplatelet agents in high doses. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | State Autonomous Health Institution "Engels City Clinical Hospital No1" | Engels | |
Russian Federation | Limited Liability Company "Professorskaya Clinica" | Perm | |
Russian Federation | Limited Liability Company "Clinika Zvezdnaya" | Saint Petersburg | |
Russian Federation | Limited Liability Company "MEDICINSKAYA CLINIKA" | Saint Petersburg | |
Russian Federation | Limited Liability Company "PeterClinic" | Saint Petersburg | |
Russian Federation | Limited Liability Company "Scientific Research Center Eco-Safety" | Saint Petersburg | |
Russian Federation | Saint Petersburg State Budgetary Healthcare Institution "State Polyclinic No. 117" | Saint Petersburg | |
Russian Federation | Limited Liability Company "Medical Center Diagnostics and Prevention Plus" | Yaroslavl |
Lead Sponsor | Collaborator |
---|---|
St. Petersburg Research Institute of Vaccines and Sera |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline geometric mean titer ratio of antibodies for each virus strain (GMT (Flu-M w/p) / GMT (Flu-M w/o/p) at 6 months | The upper limit of bilateral 95% CI for the GMT ratio (GMT (Flu-M w/p) / GMT (Flu-M w/o/p) should not exceed 1.5 | days 0-180 | |
Primary | Change from baseline the difference between seroconversion rates (seroconversion rate Flu-M w/p - seroconversion rate Flu-M w/o/p) at 6 months | The upper limit of bilateral 95% CI for the difference between seroconversion rates (seroconversion rate Flu-M w/p - seroconversion rate Flu-M w/o/p) should not exceed 10% | days 0-180 | |
Secondary | Geometric mean titer of antibodies for each virus strain (A (H1N1), A (H3N2) and B) | Specific anti-influenza antibodies were determined using haemagglutination inhibition assay (HI assay) | days 0,28,180 | |
Secondary | Seroconversion rate for each virus strain (A (H1N1), A (H3N2) and B) | days 0,28,180 | ||
Secondary | Seroconversion factor for each virus strain (A (H1N1), A (H3N2) and B) | days 0,28,180 | ||
Secondary | Seroprotection rate for each virus strain (A (H1N1), A (H3N2) and B) | days 0,28,180 | ||
Secondary | Incidence, severity, and duration of influenza or ARVI during 6 months after vaccination | days 1-180 | ||
Secondary | Incidence of adverse events (AEs) | days 1-180 | ||
Secondary | Incidence of serious adverse events (SAEs) | days 1-180 | ||
Secondary | Number of patients with abnormal results of blood pressure (BP) | BP measurements include the systolic and diastolic blood pressure.BP is measured on the brachial artery according to the Korotkoff method using a certified sphygmomanometer or tonometer. It is also allowed to use a certified electronic tonometer for measuring. | days 0,1,7,28,180 | |
Secondary | Number of patients with abnormal results of heart rate (HR) | The HR is measured during auscultation of the heart in parallel with determining the pulse rate on the radial artery (or on the carotid artery in case of weak pulsation in the radial artery) for a minute while sitting. | days 0,1,7,28,180 | |
Secondary | Number of patients with abnormal results of respiratory rate (RR) | The RR is measured for a minute at rest in the sitting position, by registering the breathing movements of the chest or abdominal wall. | days 0,1,7,28,180 | |
Secondary | Number of patients with abnormal results of body temperature (>37 °?) | Body temperature (°C) is measured with a mercury or digital thermometer in the armpit for at least 5 minutes or with a non-contact infrared digital thermometer. | days 0,1,7,28,180 | |
Secondary | Number of patients with abnormal results of physical examination | Physical examination of volunteers includes an interview, discovery of complaints and symptoms, when required, palpation, auscultation, percussion. | days 0,1,7,28,180 | |
Secondary | Number of patients with abnormal results of neurological status | Assessment of:
Cranial nerve function Motor sphere Reflex sphere Sensitive sphere Coordination sphere Pelvic functions Higher mental functions |
days 0,7,28 | |
Secondary | Determination of total IgE | days 0,7,28 | ||
Secondary | Number of patients with abnormal results of electrocardiography (ECG) | 2-lead electrocardiography (ECG). Assessment of: PQ, QT,QTc intervals, QRS complex | days 0,7 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |